{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:26:21Z","timestamp":1790745981943,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.beem.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:59:15Z","timestamp":1527314355000},"page":"657-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Paget's disease of bone"],"prefix":"10.1016","volume":"32","author":[{"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.04.024","article-title":"Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes","volume":"55","author":"Corral-Gudino","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.005_bib2","series-title":"Pathophysiology and treatment of Paget's disease of bone","author":"Kanis","year":"1998"},{"key":"10.1016\/j.beem.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1359\/jbmr.2004.19.4.566","article-title":"Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey\u2013the Rotterdam study","volume":"19","author":"Eekhoff","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S8756-3282(96)00310-9","article-title":"Evidence for secular change in Paget's disease of bone","volume":"20","author":"Cundy","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.005_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00198-012-1954-5","article-title":"Secular changes in Paget's disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain","volume":"24","author":"Corral-Gudino","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.metabol.2017.06.010","article-title":"Paget's disease of bone","volume":"80","author":"Cundy","year":"2018","journal-title":"Metabolism"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.5650140203","article-title":"Cell biology of Paget's disease","volume":"14","author":"Reddy","year":"1999","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsbmb.2004.03.023","article-title":"Paget's disease - a VDR coactivator disease?","volume":"89\u201390","author":"Kurihara","year":"2004","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.beem.2018.05.005_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI115584","article-title":"Interleukin-6: a potential autocrine\/paracrine factor in Paget's disease of bone","volume":"89","author":"Roodman","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jbmr.5650090111","article-title":"Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease","volume":"9","author":"Hoyland","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI9133","article-title":"Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone","volume":"105","author":"Menaa","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2018.05.005_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1359\/jbmr.2000.15.2.228","article-title":"1,25-dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease","volume":"15","author":"Menaa","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/jc.2007-1978","article-title":"Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease","volume":"93","author":"Matthews","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(08)61035-1","article-title":"Pathogenesis and management of Paget's disease of bone","volume":"372","author":"Ralston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2018.05.005_bib15","first-page":"85","article-title":"Pathobiology of Paget's disease of bone","volume":"21","author":"Galson","year":"2014","journal-title":"J\u00a0Bone Metabol"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2018.05.005_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.5650140207","article-title":"Update on the viral etiology of Paget's disease of bone","volume":"14","author":"Singer","year":"1999","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-017-0265-4","article-title":"Antibody response to paramyxoviruses in Paget's disease of bone","volume":"101","author":"Visconti","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1172\/JCI82012","article-title":"Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease","volume":"126","author":"Teramachi","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bone.2012.12.007","article-title":"Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3\/Sirt1 signaling","volume":"53","author":"Wang","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cmet.2010.12.002","article-title":"Contributions of the measles virus nucleocapsid gene and the SQSTM1\/p62(P392L) mutation to Paget's disease","volume":"13","author":"Kurihara","year":"2011","journal-title":"Cell Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jbmr.5650060511","article-title":"Familial aggregation of Paget's disease of bone","volume":"6","author":"Siris","year":"1991","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jbmr.5650100421","article-title":"Frequency and characteristics of familial aggregation of Paget's disease of bone","volume":"10","author":"Morales-Piga","year":"1995","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/art.20224","article-title":"Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations","volume":"50","author":"Eekhoff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S8756-3282(00)00278-7","article-title":"Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q","volume":"26","author":"Hocking","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.005_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1359\/jbmr.1998.13.6.911","article-title":"Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity","volume":"13","author":"Haslam","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib26","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/jbmr.1975","article-title":"Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease","volume":"28","author":"Albagha","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bonekey.2015.125","article-title":"Genetics of Paget's disease of bone","volume":"4","author":"Albagha","year":"2015","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.beem.2018.05.005_bib28","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/jbmr.132","article-title":"Mutations of SQSTM1 are associated with severity and clinical outcome in Paget disease of bone","volume":"25","author":"Visconti","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-008-9137-2","article-title":"Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's Disease of bone","volume":"83","author":"Chung","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00223-011-9514-0","article-title":"Familial Paget disease and SQSTM1 mutations in New Zealand","volume":"89","author":"Cundy","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/ng.562","article-title":"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone","volume":"42","author":"Albagha","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2018.05.005_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.845","article-title":"Genome-wide association identifies three new susceptibility loci for Paget's disease of bone","volume":"43","author":"Albagha","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2018.05.005_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00439-010-0888-2","article-title":"The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes","volume":"128","author":"Chung","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.beem.2018.05.005_bib34","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/jbmr.162","article-title":"Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone","volume":"25","author":"Chung","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1172\/JCI97103","article-title":"TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations","volume":"128","author":"Lee","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2018.05.005_bib36","first-page":"133","article-title":"Relation between signs and symptoms in Paget's disease of bone","volume":"58","author":"Harinck","year":"1986","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.beem.2018.05.005_bib37","first-page":"37","article-title":"Skeletal distribution and biochemical parameters of Paget's disease","volume":"217","author":"Meunier","year":"1987","journal-title":"Clin Orthoped Relat Res"},{"key":"10.1016\/j.beem.2018.05.005_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1302\/0301-620X.62B1.7351428","article-title":"Complete fractures of the femur in Paget's disease of bone","volume":"62-B","author":"Dove","year":"1980","journal-title":"J\u00a0Bone Joint Surg (British)"},{"key":"10.1016\/j.beem.2018.05.005_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jbmr.2349","article-title":"Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone","volume":"30","author":"Rendina","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajhg.2015.12.016","article-title":"ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor","volume":"98","author":"Divisato","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2018.05.005_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/cge.13247","article-title":"ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget's disease of bone","author":"Divisato","year":"2018","journal-title":"Clin Genet"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2018.05.005_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1359\/jbmr.06s218","article-title":"Medical management of Paget's disease of bone: indications of treatment and review of current therapies","volume":"21","author":"Siris","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib43","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1210\/jc.2014-2910","article-title":"Paget's disease of bone: an endocrine society clinical practice guideline","volume":"99","author":"Singer","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMcp1204713","article-title":"Paget's disease of bone","volume":"368","author":"Ralston","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.005_bib45","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone; early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate","volume":"295","author":"Harinck","year":"1987","journal-title":"Br Med J"},{"key":"10.1016\/j.beem.2018.05.005_bib46","first-page":"3993","article-title":"Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption","volume":"81","author":"Papapoulos","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-017-0261-8","article-title":"Long-term bone scintigraphy results after intravenous zoledronate in Paget's disease of bone","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2018.05.005_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","article-title":"PRISM Trial Group. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone","volume":"25","author":"Langston","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib49","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jbmr.3066","article-title":"Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ study","volume":"32","author":"Tan","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib50","doi-asserted-by":"crossref","first-page":"L47","DOI":"10.1210\/jc.2015-1961","article-title":"Response to letter by Ralston, et\u00a0al","volume":"100","author":"Singer","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib51","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/jbmr.3156","article-title":"Treating Paget's disease \u2013 why, and how much?","volume":"32","author":"Cundy","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib52","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.005_bib53","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A\u00a0single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years","volume":"26","author":"Reid","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.3029","article-title":"Durability of response to zoledronate treatment and competing mortality in Paget's disease of bone","volume":"32","author":"Cundy","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bone.2003.03.001","article-title":"Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy","volume":"33","author":"Eekhoff","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.005_bib56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2018.05.005_bib57","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":"Interleukin-6 and the acute phase reaction during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.005_bib58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.beem.2018.05.005_bib59","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00223-016-0150-6","article-title":"Treatment of Paget's disease of bone with denosumab: case report and Literature review","volume":"99","author":"Reid","year":"2016","journal-title":"Calcif Tissue Int"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18300733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18300733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:52:25Z","timestamp":1761497545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X18300733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1521690X18300733"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2018.05.005","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paget's disease of bone","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}